Filing Details
- Accession Number:
- 0000950170-24-069608
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-05 21:15:40
- Reporting Period:
- 2024-06-03
- Accepted Time:
- 2024-06-05 21:15:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1088856 | Corcept Therapeutics Inc | CORT | Pharmaceutical Preparations (2834) | 770487658 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1817838 | Douglas Joseph Lyon | C/O Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park CA 94025 | See Remarks | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-06-03 | 5,000 | $11.35 | 12,314 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-06-03 | 5,000 | $30.18 | 7,314 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-03 | 488 | $30.17 | 6,826 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2024-06-03 | 1,232 | $31.30 | 8,058 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2024-06-03 | 1,232 | $0.00 | 9,290 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | F | Direct | |
| No | 4 | A | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2024-06-03 | 5,000 | $0.00 | 5,000 | $11.35 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 14,167 | 2029-02-08 | No | 4 | M | Direct |
Footnotes
- Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $30.17 to $30.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- The closing price on May 31, 2024 was used to calculate the withholding obligation.
- The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 3, 2024.
- In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
- Fully exercisable.
Billionaire Hedge Funds
